Identifying Optimal Testing Modalities to Increase COVID-19 Testing Access: Protocol for a Household Randomized Control Trial in Baltimore, MD (Preprint)

• DOI: 10.2196/preprints.68600
• Publication Date: 2024-11-19T14:13:31Z
• Authors: Jessica Duchen; Alexandra K Mueller; Saifuddin Ahmed; Jamie Perin; Courtney Borsuk; Joshua Trowell; Kelly Lowensen; Steven Huettner; Andy Peytchev; Jason E Farley; Shruti H Mehta; Jacky M Jennings
• Keywords: Preprint; Modalities; 2019-20 coronavirus outbreak

<sec> <title>BACKGROUND</title> The COVID-19 pandemic disproportionately affected low-income, and racial ethnic minority populations. Testing plays a critical role in disrupting disease transmission, but complex barriers prevent optimal testing access, particularly for Black Latinx communities. There is limited evidence on modalities to increase access these </sec> <title>OBJECTIVE</title> primary objective of the Community Collaboration Combat (C-FORWARD) trial define maximizing acceptance, uptake, timeliness results receipt. <title>METHODS</title> C-FORWARD household-randomized comparative effectiveness conducted an urban population representative sample. Households across 653 census block groups were sampled using probability proportional size approach. outcome was completion SARS-COV-2/COVID-19 within 30 days randomization. <title>RESULTS</title> Between February 2021 December 2022. 1,083 individuals (881 index participants 202 household members) enrolled. mean age 51 (SD ±18) years. Forty-three percent identified as or African American, 48.6% white, 9.0% other, including Asian, American Indian, Native Hawaiian Pacific Islander, multiple races. Five Hispanic Latino. At time enrollment, 51.1% currently working either full part-time 32.9% had advanced degree. Eighty been tested previously, with 22.3% reporting having previously positive COVID-19, 86.8% reported receiving at least one vaccination prior enrollment. <title>CONCLUSIONS</title> Data from will be used address important questions regarding acceptance uptake population. <title>CLINICALTRIAL</title> Clinical Trials.gov ID: NCT04673292